BIO89-100 reduces liver fat, lowers triglycerides in adults with NASH

BIO89-100 reduced liver fat in adults with nonalcoholic steatohepatitis, or NASH, while also lowering triglycerides for participants taking weekly and biweekly doses, according to trial data presented at the ENDO annual meeting.“In patients with NASH, BIO89-100 has been shown to significantly decrease liver fat and liver volume as well as to have beneficial effects on common metabolic comorbidities, such as type 2 diabetes and hypertriglyceridemia,” Juan Pablo Frias, MD, medical director and principal investigator at the National Research Institute in Los Angeles, told Healio. “InRead More

Share on facebook
Share on twitter
Share on linkedin